Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eugene Laska

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Journal of Clinical Psychopharmacology|May 6, 2008
Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophreniaJohn M Kane, John Lauriello, Eugene Laska, et al.
Journal of Community Health|May 24, 2015
Outcomes of The BODY Project: A Program to Halt Obesity and Its Medical Consequences in High School StudentsVictoria Sweat, Jean-Marie Bruzzese, Arthur Fierman, et al.
General Hospital Psychiatry|March 10, 2017
Making the cut: Depression screening in urban general hospital clinics for culturally diverse Latino populationsDamara Gutnick, Carole Siegel, Eugene Laska, et al.
Addiction (Abingdon, England)|February 24, 2015
Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trialJoshua D Lee, Ryan McDonald, Ellie Grossman, et al.
Substance Use & Addiction Journal|May 5, 2025
Identifying Alcohol Use Disorder and Problem Use in Adult Primary Care Patients: Comparison of the Tobacco, Alcohol, Prescription Medication and Other Substance (TAPS) Tool With the Alcohol Use Disorders Identification Test Consumption Items (AUDIT-C)Angéline Adam, Eugene Laska, Robert P Schwartz, et al.
Schizophrenia Research|February 4, 2014
d-Cycloserine augmentation of cognitive remediation in schizophreniaChristopher K Cain, Margaret McCue, Iruma Bello, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 10, 2006
Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trialChristopher G Goetz, Philippe Damier, Christine Hicking, et al.
Addiction Science & Clinical Practice|October 17, 2019
Electronic self-administered screening for substance use in adult primary care patients: feasibility and acceptability of the tobacco, alcohol, prescription medication, and other substance use (myTAPS) screening toolAngéline Adam, Robert P Schwartz, Li-Tzy Wu, et al.
Sleep|December 6, 2003
Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomniaAndrew D Krystal, James K Walsh, Eugene Laska, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Placebo influences on dyskinesia in Parkinson's diseaseChristopher G Goetz, Eugene Laska, Christine Hicking, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Journal of Clinical Psychopharmacology|May 6, 2008
Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophreniaJohn M Kane, John Lauriello, Eugene Laska, et al.
Journal of Community Health|May 24, 2015
Outcomes of The BODY Project: A Program to Halt Obesity and Its Medical Consequences in High School StudentsVictoria Sweat, Jean-Marie Bruzzese, Arthur Fierman, et al.
General Hospital Psychiatry|March 10, 2017
Making the cut: Depression screening in urban general hospital clinics for culturally diverse Latino populationsDamara Gutnick, Carole Siegel, Eugene Laska, et al.
Addiction (Abingdon, England)|February 24, 2015
Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trialJoshua D Lee, Ryan McDonald, Ellie Grossman, et al.
Substance Use & Addiction Journal|May 5, 2025
Identifying Alcohol Use Disorder and Problem Use in Adult Primary Care Patients: Comparison of the Tobacco, Alcohol, Prescription Medication and Other Substance (TAPS) Tool With the Alcohol Use Disorders Identification Test Consumption Items (AUDIT-C)Angéline Adam, Eugene Laska, Robert P Schwartz, et al.
Schizophrenia Research|February 4, 2014
d-Cycloserine augmentation of cognitive remediation in schizophreniaChristopher K Cain, Margaret McCue, Iruma Bello, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 10, 2006
Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trialChristopher G Goetz, Philippe Damier, Christine Hicking, et al.
Addiction Science & Clinical Practice|October 17, 2019
Electronic self-administered screening for substance use in adult primary care patients: feasibility and acceptability of the tobacco, alcohol, prescription medication, and other substance use (myTAPS) screening toolAngéline Adam, Robert P Schwartz, Li-Tzy Wu, et al.
Sleep|December 6, 2003
Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomniaAndrew D Krystal, James K Walsh, Eugene Laska, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Placebo influences on dyskinesia in Parkinson's diseaseChristopher G Goetz, Eugene Laska, Christine Hicking, et al.
Pageof 5